12:12 PM EDT, 08/21/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Thursday the US Food and Drug Administration approved Dawnzera as the first and only RNA-targeted prophylactic treatment for preventing attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older.

The approval of Dawnzera was based on phase 3 results, which showed that the therapy reduced the monthly attack rate of the disease by 81% compared with placebo over 24 weeks, the company said.

Dawnzera will be available in the US in the coming days, Ionis said.

Price: 42.71, Change: -0.10, Percent Change: -0.23